Previous close | 1.3200 |
Open | 1.2900 |
Bid | 1.3100 x 300 |
Ask | 1.3200 x 300 |
Day's range | 1.2700 - 1.3700 |
52-week range | 0.3450 - 2.1050 |
Volume | |
Avg. volume | 8,932,658 |
Market cap | 339.669M |
Beta (5Y monthly) | 3.74 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Ocugen (OCGN) stock gains as the DSMB for the phase I/II study of OCU410 approves the initiation of dosing with the medium dose of OCU410 in the dose-escalation phase of the GA study.
Ocugen, Inc. (NASDAQ:OCGN) Q3 2023 Earnings Call Transcript November 9, 2023 Ocugen, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.08. Operator: Good morning and welcome to Ocugen’s Third Quarter 2023 Financial Results and Business Update. Please note that this call is being recorded at this time. All participants’ line are in a […]